2005, A Cancer Year in Review

 

2005, A Cancer Year in Review

2005 was another year in which cancer was the leading cause of death in the U.S. for people under 85. Yet, at the same time, there were many self-reliant victors with inspiring stories of survival. CancerWire focused on several of these extraordinary people and also reported on topics that enable patients to maximize their quality of life.

(PRWEB) December 29, 2005 -- 2005 has been another year in which cancer took almost twice as many lives as the number of American casualties in WWII. The human toll included:

•     1,372,910 estimated new cancer cases
•     570,280 estimated cancer deaths (295,280 men; 275,000 women; more than 1,500 deaths/day)
•     Nearly 10,000 children under 14 were diagnosed with cancer

Using estimates from the American Cancer Society, more than $70 billion dollars were spent on direct medical costs and the National Cancer Institute spent over $6 billion in cancer research. Despite all of these dollars expended on research and treatment, in 2005 cancer was the leading cause of death in adults under 85 and it continues to be the leading cause of death by disease in children. Are we really winning the “war on cancer?”

Rather than waiting for big institutions to solve our cancer problem, many patients and practitioners are finding their own answers to cancer. This year, CancerWire profiled several of them and also reported on topics that enable patients to maximize their quality of life.

Surviving Mesothelioma, a Terminal Cancer: Paul Kraus' Remarkable Story was the subject for the March, 2005 edition of CancerWire. Paul Kraus who had been diagnosed in 1997 with mesothelioma, a cancer that is aggressive and incurable with orthodox approaches. Mr. Kraus had been sent home with a “few months to live” but he is alive with good quality of life 8 years later.

Surviving Breast Cancer Using an Integrative Approach: Madeleen Herreshoff's Journey was the subject of the April edition of CancerWire. In 1991, at the age of 49, Ms. Herreshoff was diagnosed with aggressive poorly differentiated invasive breast cancer and told that without radiation, aggressive chemotherapy and 5 years of tamoxifen that she would be dead within 5 years.

Nutritional Supplement Reported to Help Cancer Patients Undergoing First Clinical Trial was the subject of the May edition of CancerWire. This supplement, Lipoic Acid Palladium Complex (LAPd) was created by Dr. Merrill Garnett, a chemist who spent over 20 years in search of a non-toxic form of chemotherapy that could be used to support more orthodox treatments.

The June edition focused on viaticals, an option for “terminal” cancer patients with life insurance. Viaticals continue to be a viable source of money for patients who do their homework and work with reputable companies… read the rest go to http://www.cancermonthly.com/individual_opp.asp

The July edition focused on Pathology Diagnosis and whether cancer patients needed a second opinion.

Obtaining Credible Information About Alternative Cancer Therapies discussed the steps to obtain credible information about vitamins, herbs and other supplements by taking advantage of the information available through the National Library of Medicine.

Folk Medicine, Herbs, and Cancer was the subject of the September edition. In this issue, we interviewed John Heinerman, Ph.D. a Medical Anthropologist who discussed what he had learned about healing cancer as a result of his visits to 33 countries.

Cancer Treatments - Responses, Survival & Placebo: Defining an Effective Cancer Therapy reported on how cancer therapies are labeled "effective" by oncologists so that cancer patients can understand what makes one treatment better than another.

And the November issue introduced our first Best Cancer Books edition.

To read these stories go to: http://www.cancermonthly.com

Cancer Monthly would like to wish our readers a happy, healthy, and prosperous 2006.

More information:
•     Read the whole story http://www.cancermonthly.com
•     To subscribe to CancerWire http://www.cancermonthly.com/cancerwire.asp
•     For more information about immune boosting products in cancer http://www.cancermonthly.com/immune.asp
•     For more information about clinics that treat cancer http://www.cancermonthly.com/clinics.asp
•     For more information about financial support for cancer patients http://www.cancermonthly.com/financial.asp
•     For more information about legal options for mesothelioma patients http://www.cancermonthly.com/legal_services.asp

Of course, none of this information in CancerWire is a substitute for professional medical advice, examination, diagnosis or treatment and you should always seek the advice of your physician or other qualified health professional before starting any new treatment or making any changes to an existing treatment. No information contained in Cancer Monthly or CancerWire including the information above, should be used to diagnose, treat cure or prevent any disease without the supervision of a medical doctor.

# # #

Press Contact: Michael Horwin
Company Name: CANCER MONTHLY
Email: email protected from spam bots
Phone: 919-570-8595
Website: www.cancermonthly.com

Who's on the List to Receive Antiviral Treatment?

 

The Government's 'Unspoken Acknowledgment': Who's on the List to Receive Antiviral Treatment?

The federal plan to stockpile antiviral medications will not be able to support the entire US population. Therefore, the government recommends "priority groups" to determine who will be allowed treatment in the event of an avian flu pandemic. The small supply of medications will need to be used effectively and efficiently, while keeping in mind the groups at high-risk and rates for spread of infection. Because children and the elderly contribute greatly to infection rates and are more susceptible to disease, it is imperative that the government keep this in mind.

Bethesda, MD (PRWEB) December 27, 2005 -- In advance of an avian flu pandemic, the government is preparing to stockpile quantities of antiviral drugs as an early response plan to curtail the spread of infection. The Department of Health and Human Services anticipates that stockpiled antivirals will be sufficient to treat 25% of the US population. However, the current quantity of antiviral drugs may be as low as only 2% for the American public, and the timeline to produce sufficient quantities years out. This ultimately begs the question of how the government plans to distribute and prioritize an extremely limited amount of medication to most effectively serve the public good.

Recently, representatives from the International Association of Medicinal Compliance (IAMC) and FLAVORx, Inc. have been meeting with members of Congress to propose an effective response to the avian flu. Top government leaders hint at an ‘unspoken acknowledgement’ regarding the “priority groups” to receive antiviral treatment. At the top of the list are key decision makers and essential service providers. Immediately following these groups are medical personnel working closely with avian flu cases and research and pharmaceutical manufacturers capable of producing more antivirals or deriving an effective avian flu vaccine. “But what about children? Or the elderly? Or those with compromised immunity?” asks Gunjan Koul, Program Director for the IAMC. “What process is our government using to determine who is eligible for treatment when the reality of who spreads it most isn’t even addressed?”

The CDC suggests that the priority of groups to receive the human influenza vaccine begins with children aged 6-23 months, adults 65 and older and those at high risk for developing serious medical conditions such as those with pre-existing chronic disease states “So why would these same high risk groups not be a top priority in the avian flu pandemic?” says Koul. “Pandemic spread is determined by the rate of infection. If the government can’t protect those most prone to contracting or spreading the virus, then no amount of antiviral medication will be sufficient to stop it.”

Studies show that children play a considerable role in disease transmission, with 45% of school-age children normally infected during an influenza outbreak. Children are at an increased risk for influenza-related hospitalizations and much more likely to spread infection to other children, family members and even out-of-home caregivers. According to the National Institute of Allergy and Infectious Disease (NIAID) “because schools are an excellent place for flu viruses to attack and spread, families with school-age children have more infections than other families, with an average of 1/3 of the family members infected each year.” Senator Kennedy’s Science and Policy Office notes that “vaccinating 80% of children is as good at slowing the spread of flu as vaccinating 80% of the total population.”    

The WHO suggests administering the human influenza vaccine to reduce the potential for people to be infected with the avian flu and concurrently infected with the human influenza strain. Dual infection increases the opportunity for genetic reassortment of the avian strain with genes from the human strain, which could result in a mutated, more potent pandemic strain. Because children and the elderly are at higher risk for contracting the human flu virus, additional infection with the avian flu virus could show exponentially detrimental damage to public health as a whole.

Earlier this year, the first wave of avian flu vaccine development yielded positive results in the testing of healthy adults. However according to So. Captain Charles Baxter of the US 7th Fleet, “a vaccine for the avian flu has yet to be invented and it probably won’t until the disease reaches pandemic state.” Beyond that, trials must also be conducted to determine the effectiveness and safety in children.

But without an effective vaccine yet available, or without the guarantee that a vaccine will be safe for children and the elderly, Koul wonders how they will protect these groups. Recent events also show that a higher dosage, and thus a larger quantity of Tamiflu suspension, might be needed to suppress the effects of avian flu symptoms and mortality. The IAMC and FLAVORx have proposed that, in light of this information on influenza susceptibility and disease spread, the focus for prioritizing distribution of antiviral medications be placed on children and the elderly. To ensure that these drugs are used as effectively as possible, patients must adhere to near 100% medicinal compliance. For children and the elderly, studies show that non-compliance is typically the result of taste and palatability in swallowing medications. FLAVORx’s continual studies on antiviral medications like Tamiflu conclude that the liquid suspension has an extremely bitter aftertaste and systemic effect, unpleasantly remaining on the taste buds for several hours to days. This can be easily overcome with the addition of a medically designed flavoring. In the event of an avian flu pandemic, it is imperative that the government be prepared with a comprehensive plan that addresses all aspects, details and risks associated with the spread of infection to successfully protect the public health.

For more information, please contact Teresa Chen at 253.569.1087.

###

Press Contact: Teresa Chen
Company Name: FLAVORX, INC.
Email: email protected from spam bots
Phone: 240.223.0953
Website: www.flavorx.com

Attorney Publishes Book on Jury Selection

 

Baron & Budd Attorney Lisa Blue Publishes Book on Jury Selection

 

DALLAS, Texas (January 26, 2005) - Lisa Blue, PhD, an attorney with the law firm of Baron & Budd, P.C., has just released “Blue’s Guide to Jury Selection,” published by Thomson West and the Association of Trial Lawyers of America.  Co-authored with jury consultant Robert Hirschhorn, the Blue Guide walks the reader through every aspect of voir dire from logistical considerations such as pre-trial motions and jury questionnaires to developing the art of effective communication with jurors through the use of psychological techniques as well as an understanding of body language—just to name a few of the topics covered in this in-depth book.

 

“Our primary goal in writing this book is to help attorneys feel more comfortable in front of the jury during voir dire,” said Dr. Blue.  “We think lawyers at every level--from first-year associates to seasoned veterans--will be better at jury selection after reading this book.”

 

A trial lawyer and licensed psychologist, Dr. Blue has represented hundreds of victims of mesothelioma caused by asbestos exposure and diseases caused by other toxic substances, honing her skills as an expert on jury selection and trial psychology.  She is certified by the American Board of Forensic Psychology and by the American Board of Professional Psychology. The National Law Journal recognized Dr. Blue in 2001 as one of the top 50 women litigators in the U.S. for her accomplishments in trial courts around the country.

 

About Baron & Budd, P.C.

Since 1977, the law firm of Baron & Budd, P.C. has championed the rights of people and communities harmed by corporate misconduct. With over 70 attorneys and offices in Texas, Illinois, Ohio, Louisiana, and New York, Baron & Budd enjoys a national reputation as a leader of the plaintiffs’ bar. The firm represents individuals with mesothelioma and other diseases caused by asbestos; leukemia caused by benzene; injuries caused by other toxic substances and unsafe pharmaceuticals; water authorities seeking clean-up costs for drinking water contamination; securities investors defrauded by corporate wrongdoing; and consumers in class actions.  For more information on the firm, call 1-800-222-2766 or visit www.baronandbudd.com.

Avoid Online Drug Scams

Avoid Online Drug Scams

FOR IMMEDIATE RELEASE:

Lakewood, WA (OPENPRESS) October 21, 2005 -- Consumers Discount Rx and Trusted Online Prescriptions succeed in returning honesty and trust to purchasing online prescriptions.

Insurance costs and lawsuits are continually driving up the price of drugs. As a result, more and more online drug stores are selling poor quality and illegal medications disguised as fast, reliable and real. Purchasing these drugs is a costly and potentially unhealthy mistake many consumers make.

Consumers Discount Rx achieves where others do not. It offers savings of up to 60 percent, free consultations by U.S. licensed physicians and next day FedEx shipping. All major FDA-approved drugs are available. Products are genuine and could not be sold legally without government approval. This provides the consumer an easy and dependable way to order and purchase their desired prescriptions and to avoid paying super-inflated overhead costs. Most importantly, consumers can do so from the security of home.

Unfortunately, black market drug selling does indeed exist, as do websites offering cheap drugs without disclosing hidden costs or divulging the origins of the products. Most people would agree that not all companies are equal. People want genuine products, an opportunity to save money and the ability to trust.

Trusted Online Prescriptions is an affiliate of CDRx and provides precisely what its name says. It is listed among many popular search engines and is continually expanding its global market. Its goal is that more and more people will find new confidence in purchasing legal prescription medication from their homes.

Consumers Discount Rx.com, Inc. and AmeriMedRx Industries, LCC together (cdrx.AmeriMedRx) form one of the most trusted online medical offices. It offers medical consultation by U.S. licensed physicians, pharmacists and pharmacy technicians, FDA-approved pharmaceuticals and prescription processing.

Currently reaching 59 countries worldwide, it respects the Internet as a means to provide to anyone, anywhere and at anytime. It believes in discreet and confidential service. The company and its affiliates are a family dedicated to pursuing integrity and satisfaction--a goal that is reflected in its clients' testimonies and returning business.

###
Professional Free Press Release News Wire

Contact Info

Trusted Online Prescriptions
Phone: (253) 588-8660
E-mail: Click Here to Send
Web site: http://www.consumersdiscountrx.com/elambert

7307 95th Ave. SW
Lakewood, WA 98498

Prescription Drug Plan Study Projects 47% Savings for Medicare Enrollees

 

Copay Solutions Study Projects 47% Savings for Medicare Enrollees under Prescription Drug Plan

National study of Medicare Drug Plan enrollees finds average enrollee will save 47% by enrolling in a plan. Humana is most aggressive bidder on Drug Plan business.

Los Gatos, CA (PRWEB) December 19, 2005 -- A study released today by Copay Solutions found that enrollees in a Medicare Prescription Drug Plan can expect to save 47% from their current annual drug spend. On average, enrollees in the study were paying $3,685 per year for 5.4 prescription drugs. By enrolling in the Medicare Prescription Drug Plan with the lowest total cost, enrollees were able to reap projected savings of $1,741 or 47% of their current annual drug spend.

While the study analyzed Prescription Drug Plan offerings from all of the insurers involved in the Medicare Drug Program, it found that Humana offered the lowest-cost plan to more than 50% of the enrollees.

The study consolidated data from Medicare websites with data collected from enrollees for such items as current drugs, dosage, and cost. The survey sample included 100 enrollees from 93 different zip codes across the U.S.

“Our analysis indicates that the Medicare Drug Program is a solid program and one that has the potential to save people real money,” said George D. Pillari, CEO of Copay Solutions. “We consider this to be a flash estimate of the potential effect of the Medicare Drug Program on the Medicare population and on the organizations offering Prescription Drug Plan insurance products,” he added.

Anecdotally, the Company cited two primary complaints from enrollees who were considering the new Program:

• The belief that the Program was only for low-income citizens and the perceived lack of eligibility led to a lack of interest, and

• The plan selection process was overly complex. Since every plan has a different formulary, deductible and copayment structure, consumers were having difficulty identifying the most important elements in a purchasing decision.

Mr. Pillari added, “Despite the difficulties involved in the plan selection and enrollment process, Medicare enrollees should take the time to identify and enroll in a plan and take advantage of the savings opportunity. The numbers are compelling.”

Copay Solutions is an independent company that helps consumers manage out-of-pocket pharmaceutical and medical costs. http://www.copaysolutions.com

###

Press Contact: Sabrina Martinez
Company Name: COPAY SOLUTIONS
Email: email protected from spam bots
Phone: 800-331-2203
Website: www.copaysolutions.com

ePharmacies.com Launches Highest Paying Affiliate Program in the Industry

 

ePharmacies.com Launches Highest Paying Affiliate Program in the Industry

ePharmacies.com has launched their long awaited affiliate program through ShareaSale.com paying a record setting 47% commission on 1st tier and 11% on 2nd tier conversions.

(PRWEB) December 14, 2005 -- This week, ePharmacies.com launched their long awaited affiliate program through ShareaSale.com. With the site providing monthly memberships to users seeking to find prescriptions online, publishers already have the advantage of tapping into one of the largest industries on the Web. With a market this large and the best affiliate program payouts available, there is enormous mutual potential for both ePharmacies.com and their affiliates.

Even the top affiliate programs in the pharmaceutical industry have never broken the 30% commission rate ceiling. ePharmacies.com is shattering that ceiling by offering their affiliates a 47% commission rate on new registrations. They are also providing their affiliates with a 2nd tier where they can earn 11% from any of their sub-affiliates. Online affiliate programs come in all shapes and sizes, but the numbers rarely lie. Current ePharmacies.com affiliates are seeing as high as a 2.77% conversion ration for their traffic, also shattering industry standards to date.

Publishers interested in the ePharmacies.com affiliate program need only go to the website. They provide their affiliates with all of the tools necessary to close the deal with those potential leads. Keyword optimized text links, attractive and inviting banners, and great informational resources are available with the help of ShareaSale.com. Few of the highest paying affiliate programs also go to the lengths that ePharmacies does to help their publishers maximize their conversions.

Perhaps the most useful resources that are provided in the ePharmacies.com affiliate program are their tips and tricks, specifically geared for the pharmaceutical industry. You can get great advice about where to get new exposure, how to best convert traffic to sales, and much more. This resource truly sets ePharmacies.com apart from other pharmacy affiliate programs.

To start your partnership with ePharmacies.com, visit their affiliate page here: http://www.epharmacies.com/affiliatemarketing.aspx. Between their low prices, high commissions, and helpful resources, both ePharmacies.com and all of their affiliates should benefit tremendously from these relationships for a long time to come.

About ePharmacies.com
ePharmacies.com is an independent web site that is based entirely on members' feedback. Their international database of online pharmacies also includes Mexican and Canadian pharmacies. For more information, visit www.epharmacies.com.

Media Contact:
Joshua Daly
210-789-2973

# # #

Press Contact: Joshua Daly
Company Name: ePharmacies.com
Email: email protected from spam bots
Phone: 210-789-2973
Website: http://www.epharmacies.com

Consumers Safely Find Cheap Prescription Drugs With Discount Coupons and Callback Buttons

 

Newly Released Discount Coupons and Callback Buttons Help Consumers Safely Find Cheap Prescription Drugs

By introducing discount coupons on prescription drugs combined with callbacks from verified sources online pharmacy guide, RefillPill.com, connects shoppers to licensed pharmacies.

(PRWEB) December 14, 2005 -- RefillPill.com, a leading online destination to find medication, has released an online discount coupon on prescription drugs from Canada. By introducing discount coupons on prescription drugs combined with callbacks from verified sources online pharmacy guide, RefillPill.com, connects shoppers to licensed pharmacies. The coupon is available on www.RefillPill.com/index.html. The coupon is designed for online shoppers who are looking to buy cheap drugs from legitimate sources. Consumers get an online discount coupon on their preferred medication as well as a callback from a licensed pharmacy at zero cost.

Everyday in the United States there are patients who pay for their prescription drugs entirely out-of-pocket. Lack of health insurance extends beyond the poor and elderly to the working class and the self-employed. But they all share one thing in common - they pay too much for their drugs, especially when they can be mailed to their doorstep for half the cost. So why aren’t more Americans buying their medications from Canadian pharmacies where they can save 40–70%?

Unfortunately, research indicates that they don’t know how to do it safely, and as a result inexperienced consumers buy from online sources without a valid prescription. This practise is not authorized by the FDA. Consumers who purchase drugs without a prescription run the risk of receiving counterfeited products. To be on the safe side RefillPill.com suggests considering the following special offer on how to order drugs easily and confidentially from a licensed pharmacy in Canada.

1. Go to www.refillpill.com and fill out the coupon-survey for free.
2. Request a call from our call center agents to take advantage of a $10.00 discount on your first order.
3. Mail or fax your valid prescriptions – Toll Free - directly to a licensed and legitimate Canadian online pharmacy.
4. Get a check for $50.00 for each referral who spends more than $100 on the first purchase.

This special offer provides you with savings up to 60% on Fosamax, Zocor, Norvasc, Pravachol and 6000 other brand and generic medications! Free shipping included on all orders over $39.00.

About the Author
Basilo Paul is an editor at RefillPill.com, which is an online resources designed to help you find medications for less. Providing discount coupons on drugs as well as the most up-to-date directory of prescription services available, offers trusted health information and the ability for users to rate and compare online pharmacies. Join the Forum to discuss your personal needs now. Visit www.RefillPill.com - making drugs affordable.

# # #

Press Contact: Basilo Paul
Company Name:
Email: email protected from spam bots
Phone: +41-71-740-1629
Website: www.RefillPill.com

Asbestos Bill Likely to Hit Senate Floor Early Next Year

 

Asbestos Bill Likely to Hit Senate Floor Early Next Year

AsbestosNews.com takes stance on proposed Asbestos Bill. This bill essentially puts a cap on money compensated for asbestos exposed mesothelioma victims'.

(PRWEB) December 5, 2005 -- Asbestosnews.com has decided that the proposed asbestos "trust-fund" bill facing a Senate vote as early as next year is an unfair addition to the legal landscape as well as the United States Justice system. The bill, which has been waiting for a vote since 2003, was introduced by Senate Majority Leader Bill Frist (R - TN) in order to save companies from potentially bankrupting lawsuits stemming from asbestos related injuries.

During most of the 20th century, Asbestos was long used in building construction, fireproofing and insulation in residencies and businesses in the United States and the world. Asbestos exposure has been linked to several health problems including the development of a rare and deadly cancer known as mesothelioma. Because the cancer is hard to detect until it is too late, mesothelioma often results in death.

The proposed Asbestos Bill would create a $140 billion trust fund. This would be made up of money from businesses to compensate those who were seeking retribution for their asbestos related injuries. This fund would essentially put a cap on the amount that people would be able to recoup as well as prevent businesses from paying the bulk of the lawsuit money.

Currently, the bill is set up to allow any additional funds over the $140 billion amount to be paid out by the US taxpayers themselves, through government loans. New Hampshire Republican Sen. Judd Gregg and ranking Democrat Sen. Kent Conrad of North Dakota, have called on Sen. Frist to address the issue of where the money would come from once the fund ran out. The two senators have expressed concern that the governmental contribution to the fund would further increase the country's debt, already at its highest level ever at over $8 trillion.

Asbestosnews.com is joining the others that are concerned about the asbestos bill as it stops the rights of millions of asbestos sufferers from reclaiming their lives and their rights. By creating a capped trust fund bill to be funded largely by the US government, the responsibility is out of the hands of the businesses that long covered up the hazards of asbestos exposure. These businesses stand to resolve their culpability in their direct negligence and potentially illegal business practices. Due to some harsh critics in the Senate and elsewhere, the passing of the bill is unlikely at this juncture, but still has many proponents in both the Democratic and Republican parties.

###

Press Contact: Judie Long
Company Name: Brett Coon & Associates
Email: email protected from spam bots
Phone: 1-866-335-2666
Website: http://www.asbestosnews.com